Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
AIDS Behav (2017) 21:S23–S33 DOI 10.1007/s10461-016-1670-9
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
Technical Brief
HIV patient monitoring and case surveillance
WHO/HIV/2017.11
Supplement article
The Journal of Infectious Diseases® 2017;216(S7):S675–8
DOI: 10.1093/infdis/jix368
Finding the Missing Tuberculosis Patients • JID 2017:216 (Suppl 7) • S675
Downloaded from https://academic.oup.com/jid/article-abstract/216/suppl_7/S675/4595547
by guest on 13 Nove...mber 2017
more
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period 5-11 November 2017 and includes updates on measles, rubella, chikungunya, West Nile virus, Plague, monkeypox, legionnair...es's disease, influenza and Marburg virus disease.
more
Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
National Tuberculosis and Leprosy Conrol Programme
Guidelines for treatment of drug-susceptible tuberculosisand patient care
2017 Update
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more